Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Vitreoretinal Disorder Market Grown from 2024 to 2025?

The market size for vitreoretinal disorders has seen a significant increase in recent times. It is projected to expand from $4.30 billion in 2024 to $4.64 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%. The growth observed in the historic period can be credited to factors such as increased diabetic retinopathy prevalence, growth of the aging populace, enhanced awareness about retinal diseases, the development of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.

What Growth Rate Is Anticipated for the Vitreoretinal Disorder Market in the Coming Years?

The market for vitreoretinal disorders is predicted to experience robust growth in the coming years, ascending to $6.30 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. This projected growth during the forecast period can be credited to factors such as the surging prevalence of age-related macular degeneration, a rise in cases of diabetic retinopathy, increased investment in regenerative stem cell treatments, higher spending on eye health, enhanced awareness about the importance of early detection of retinal diseases, and government-led initiatives. The forecast period also anticipates major trends like the use of artificial intelligence (AI) in retinal disease detection, robotic assistance in vitreoretinal surgeries, nanotechnology in medicine delivery, smart contact lenses for real-time eye tracking, ultra-high-resolution through adaptive optics imaging, and biodegradable intravitreal implants.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23574&type=smp

Who Are the Leading Companies in the Vitreoretinal Disorder Market?

Major companies operating in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd. , Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical.

What Are the Key Drivers of the Vitreoretinal Disorder Market?

The increase in cases of diabetic retinopathy is anticipated to propel the expansion of the vitreoretinal disorder market. Diabetic retinopathy, a condition affecting the eye due to damage to the retina’s blood vessels caused by elevated blood sugar levels in diabetic individuals, is becoming increasingly common. This is due to the upward trend of diabetes incidence, linked to inactive lifestyles and inadequate blood sugar management, resulting in harm to retinal blood vessels. Effective management of vitreoretinal disorders is instrumental in addressing diabetic retinopathy. It deals with complications such as vitreous haemorrhage and tractional retinal detachment, hence preserving vision and circumventing additional retinal harm. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, stated in October 2024 that in 2022-23, 1.8% of First Nations people in Australia who were screened received treatment for diabetic retinopathy. This was a lower age-standardized treatment rate (1.3%) than that of non-Indigenous Australians (1.5%). Consequently, the upward trend in diabetic retinopathy cases is fueling the expansion of the vitreoretinal disorder market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23574&type=smp

What Are the Key Market Segments in the Vitreoretinal Disorder Industry?

The vitreoretinal disorder market covered in this report is segmented –

1) By Type: Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Other Types

2) By Diagnosis: Digital Fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Other Diagnosis

3) By Treatment: Surgery, Medication, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Retinal Tear: Atrophic Retinal Tear, Operculated Retinal Tear, Horseshoe Retinal Tear, Giant Retinal Tear

2) By Retinal Detachment: Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Exudative Retinal Detachment

3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema

4) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration

5) By Macular Hole: Full-Thickness Macular Hole, Lamellar Macular Hole, Tractional Macular Hole

6) By Other Types: Epiretinal Membrane, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinitis Pigmentosa, Uveitis, Vitreous Hemorrhage, Macular Edema, Central Serous Retinopathy, Proliferative Vitreoretinopathy

What Are the Latest Trends in the Vitreoretinal Disorder Market?

Leading businesses in the vitreoretinal disorder market are striving to create innovative treatments like methotrexate to cater to the unfulfilled healthcare needs related to unusual and aggressive retinal cancers. The use of methotrexate for treating primary vitreoretinal lymphoma involves the intravitreal application of a chemotherapy drug to target and inhibit malignant cells in the retina and vitreous, providing a localized and effective therapy for this rare ocular cancer. For instance, Aldeyra Therapeutics Inc., a biotechnology firm based in the USA, disclosed a successful pre-NDA meeting with the FDA in December 2022 about ADX-2191, a new, preservative-free version of methotrexate for treating primary vitreoretinal lymphoma (PVRL), an uncommon and hostile retinal cancer.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report

What Are the Key Regional Markets in the Vitreoretinal Disorder Industry?

North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23574

This Report Delivers Insight On:

1. How big is the vitreoretinal disorder market, and how is it changing globally?

2. Who are the major companies in the vitreoretinal disorder market, and how are they performing?

3. What are the key opportunities and risks in the vitreoretinal disorder market right now?

4. Which products or customer segments are growing the most in the vitreoretinal disorder market?

5. What factors are helping or slowing down the growth of the vitreoretinal disorder market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model